John T. Rudy
Member / Co-chair, Securities & Capital Markets Practice
+1.617.348.3050
John’s practice focuses on the representation of public and private companies and investment banks in capital markets transactions. He also advises public and private companies and investors in connection with mergers and acquisitions, equity and debt financings, and securities and general corporate matters.
Prior to joining Mintz, John was an associate at Davis Polk & Wardwell, LLP in New York, and at Willkie Farr & Gallagher, LLP in New York and London.
John received his J.D. from University of Pennsylvania Law School. He received a B.S.F.S. from Georgetown University School of Foreign Service. During law school, he was an associate editor of the Journal of International Economic Law.
John is admitted to practice in Massachusetts and New York.
viewpoints
Frequently Asked Questions for Private Companies Considering a Reverse Merger
February 13, 2024 | Article | By William Hicks, John T. Rudy
Reverse mergers aren’t an alternative to an IPO, rather they can be a strategic approach for companies looking to go public by leveraging “fallen angels”. Mintz Members Bill Hicks and John Rudy answer frequently asked questions for private companies considering a reverse merger in an article featured in PitchBook’s 2023 Annual US VC Valuations Report. The authors detail the benefits and challenges associated with a reverse merger including finding partners, PIPE financing, Nasdaq access for non-US companies, and SEC implications.
News & Press
Mintz Advises Aspen Aerogels on $98M Follow-on Offering
November 19, 2024
Mintz advised Aspen Aerogels, Inc. (NYSE: ASPN), a technology leader in sustainability and electrification solutions, on a registered follow-on offering of 4,887,500 shares of its common stock, which included 637,500 shares pursuant to the underwriters’ option to purchase additional shares of its common stock. The price to the public in the offering was $20.00 per share and the gross proceeds to Aspen from the offering were approximately $98 million, before deducting underwriting discounts and commissions and estimated offering expenses.
Mintz Advises ArriVent BioPharma on $175M Nasdaq IPO
February 01, 2024
Mintz Members John Rudy and Matthew T. Simpson led the team that advised ArriVent Biopharma, Inc. on its initial public offering (IPO) on the Nasdaq Global Market. This was the second biotech IPO of 2024. ArriVent is a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics.
Companies Beef Up Risk Disclosures As Biden Era Begins
February 22, 2021
Mintz Advises NexImmune in its Upsized $126.5 Million IPO
February 17, 2021
Mintz Represents Viela Bio in its IPO
October 04, 2019
Time Is Quickly Running Out for the First Quarter's IPO Hopefuls
January 24, 2019
Four Mintz Attorneys Selected for Boston’s Future Leaders Program
February 12, 2014
Events & Speaking
Disclosure, Financing, and Executive Compensation Basics for New and Aspiring Public Company Executives
Boston Bar Association
Webinar
Everything Life Sciences Companies Need to Know to Navigate the COVID-19 Pandemic
View the Webinar Recording
Recognition & Awards
Included on the Massachusetts Super Lawyers list: Rising Star – Securities & Corporate Finance (2013 – 2014, 2017 – 2019)
Greater Boston Chamber of Commerce: Boston’s Future Leaders (2014)
Recent Insights
Mintz advised Aspen Aerogels, Inc. (NYSE: ASPN), a technology leader in sustainability and electrification solutions, on a registered follow-on offering of 4,887,500 shares of its common stock, which included 637,500 shares pursuant to the underwriters’ option to purchase additional shares of its common stock. The price to the public in the offering was $20.00 per share and the gross proceeds to Aspen from the offering were approximately $98 million, before deducting underwriting discounts and commissions and estimated offering expenses.
Frequently Asked Questions for Private Companies Considering a Reverse Merger
February 13, 2024| Article|
Mintz Members John Rudy and Matthew T. Simpson led the team that advised ArriVent Biopharma, Inc. on its initial public offering (IPO) on the Nasdaq Global Market. This was the second biotech IPO of 2024. ArriVent is a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics.
